Fundraising FoxLongwood Fund — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)inLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in
Co-investorsMPM BioImpact8VCMRL Ventures FundOno Venture Investment, Inc.
The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.
ConsumerGamingHealthtechBoston, US
Robert Kotin(Executive Officer, Director)Chen Schor(Director)Robert Hadfield(Executive Officer)John Lawrence(Executive Officer)
BoardGeeta Vemuri(Director)inDerek Yoon(Director)in
Board seatDavid Steinberg· per SEC Form D
Co-investorsAstellas Venture Management LLCDC Investment PartnersSolasta VenturesUTokyo Innovation Platform Co. Ltd.Agent Capital
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatShaan C. Gandhi· per SEC Form D · $75M raise · filed Aug 2022
Co-investorsAtlas VentureLightstone VenturesPivotal Life SciencesVida VenturesHatteras Venture Partners
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalAsahi Kasei Corporate Venture CapitalDementia Discovery FundF-Prime CapitalJeito CapitalSR One Capital Management+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.